Immunitybio to showcase advances for bladder and prostate cancer at american urological association (aua) annual meeting

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a leading immunotherapy company, will announce new clinical findings for anktiva® (nogapendekin alfa inbakicept-pmln) in non-muscle invasive bladder cancer carcinoma in situ (nmibc cis) and updated data on papillary disease without cis at the american urological association annual meeting (aua 2025) in las vegas, april 26-29. the company will also host an educational and peer-networking event to discuss immunitybio's approa.
IBRX Ratings Summary
IBRX Quant Ranking